ES2235770T5 - Produccion de vacunas. - Google Patents
Produccion de vacunas. Download PDFInfo
- Publication number
- ES2235770T5 ES2235770T5 ES00204190T ES00204190T ES2235770T5 ES 2235770 T5 ES2235770 T5 ES 2235770T5 ES 00204190 T ES00204190 T ES 00204190T ES 00204190 T ES00204190 T ES 00204190T ES 2235770 T5 ES2235770 T5 ES 2235770T5
- Authority
- ES
- Spain
- Prior art keywords
- virus
- cell
- cells
- per
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 44
- 241000700605 Viruses Species 0.000 claims abstract description 187
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 26
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 11
- 230000002068 genetic effect Effects 0.000 claims abstract description 8
- 101150029662 E1 gene Proteins 0.000 claims abstract description 6
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 274
- 101710154606 Hemagglutinin Proteins 0.000 claims description 57
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 57
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 57
- 101710176177 Protein A56 Proteins 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 52
- 241000712461 unidentified influenza virus Species 0.000 claims description 49
- 239000000185 hemagglutinin Substances 0.000 claims description 42
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 210000005260 human cell Anatomy 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 21
- 241000702670 Rotavirus Species 0.000 claims description 15
- 241000710799 Rubella virus Species 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 108010006232 Neuraminidase Proteins 0.000 claims description 10
- 102000005348 Neuraminidase Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000013595 glycosylation Effects 0.000 claims description 10
- 238000006206 glycosylation reaction Methods 0.000 claims description 10
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 241000709661 Enterovirus Species 0.000 claims description 4
- 208000005577 Gastroenteritis Diseases 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 206010003399 Arthropod bite Diseases 0.000 claims description 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 241000710777 Classical swine fever virus Species 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000150452 Orthohantavirus Species 0.000 claims description 2
- 241000150350 Peribunyaviridae Species 0.000 claims description 2
- 241000710778 Pestivirus Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 2
- 208000004374 Tick Bites Diseases 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 102200157658 rs1555229948 Human genes 0.000 claims 7
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 230000001323 posttranslational effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 93
- 206010022000 influenza Diseases 0.000 description 46
- 102000004142 Trypsin Human genes 0.000 description 32
- 108090000631 Trypsin Proteins 0.000 description 32
- 239000012588 trypsin Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 30
- 238000003556 assay Methods 0.000 description 26
- 230000035931 haemagglutination Effects 0.000 description 25
- 238000010166 immunofluorescence Methods 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 22
- 235000013601 eggs Nutrition 0.000 description 21
- 239000002609 medium Substances 0.000 description 19
- 239000000787 lecithin Substances 0.000 description 18
- 235000010445 lecithin Nutrition 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 230000035899 viability Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000009385 viral infection Effects 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- 239000006180 TBST buffer Substances 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 108010076089 accutase Proteins 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000012510 hollow fiber Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000011218 segmentation Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000712431 Influenza A virus Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 235000011089 carbon dioxide Nutrition 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 208000037797 influenza A Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 241000282339 Mustela Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 241000702646 Rhesus rotavirus Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000011143 downstream manufacturing Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 229960000380 propiolactone Drugs 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000617996 Human rotavirus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000027645 antigenic variation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241001256489 Maackia <snail> Species 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000282338 Mustela putorius Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36251—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203983 | 1999-11-26 | ||
| EP99203983A EP1103610A1 (en) | 1999-11-26 | 1999-11-26 | Production of vaccines from immortalised mammalian cell lines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2235770T3 ES2235770T3 (es) | 2005-07-16 |
| ES2235770T5 true ES2235770T5 (es) | 2009-05-01 |
Family
ID=8240914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00204190T Expired - Lifetime ES2235770T5 (es) | 1999-11-26 | 2000-11-24 | Produccion de vacunas. |
Country Status (21)
| Country | Link |
|---|---|
| EP (3) | EP1103610A1 (pt) |
| JP (1) | JP4331432B2 (pt) |
| KR (2) | KR20060107868A (pt) |
| CN (1) | CN1306033C (pt) |
| AT (1) | ATE286537T1 (pt) |
| AU (2) | AU775966B2 (pt) |
| BR (1) | BR0015846A (pt) |
| CA (1) | CA2392653C (pt) |
| DE (1) | DE60017234T3 (pt) |
| DK (1) | DK1108787T4 (pt) |
| EA (1) | EA006136B1 (pt) |
| ES (1) | ES2235770T5 (pt) |
| HK (1) | HK1057236A1 (pt) |
| IL (2) | IL149788A0 (pt) |
| MX (1) | MXPA02005237A (pt) |
| NO (1) | NO333527B1 (pt) |
| NZ (1) | NZ527942A (pt) |
| PT (1) | PT1108787E (pt) |
| SI (1) | SI1108787T2 (pt) |
| WO (1) | WO2001038362A2 (pt) |
| ZA (1) | ZA200204078B (pt) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1445322T4 (da) | 1995-06-15 | 2012-09-03 | Crucell Holland Bv | Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| WO2003048197A1 (en) * | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production and of viruses, viral isolates and vaccines |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| WO2004042042A1 (en) * | 2002-11-08 | 2004-05-21 | Crucell Holland B.V. | Vaccines against west nile virus |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7425437B2 (en) | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7449324B2 (en) | 2002-02-21 | 2008-11-11 | Vironovative Bv | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
| PL213926B1 (pl) | 2001-01-19 | 2013-05-31 | Vironovative Bv | Wyizolowany ssaczy metapneumowirus o ujemnej pojedynczej nici RNA (MPV), kompozycja immunogenna, wyizolowane kwasy nukleinowe, sposoby wykrywania ssaczego metapneumowirusa, wektor, komórka gospodarza, wyizolowane bialko, przeciwcialo, sposób wirologicznego diagnozowania infekcji MPV, sposób serologicznego diagnozowania infekcji MPV, kompozycja farmaceutyczna, zestaw diagnostyczny oraz zastosowanie kompozycji farmaceutycznej |
| US8715922B2 (en) | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| EP1256803A1 (en) | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Methods for the identification of antiviral compounds |
| AU2002351444B2 (en) * | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| CA2470579C (en) * | 2001-12-17 | 2012-03-06 | Crucell Holland B.V. | Production of f(ab')2 fragments in mammalian cells |
| DE60323080D1 (de) | 2002-04-25 | 2008-10-02 | Crucell Holland Bv | Stabile adenovirale vektoren und methoden für deren vermehrung |
| CA2501975A1 (en) * | 2002-12-20 | 2004-07-08 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| JP2006524511A (ja) * | 2003-04-25 | 2006-11-02 | メッドイミューン バクシーンズ，インコーポレイティド | メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン |
| EP1623023B1 (en) | 2003-05-09 | 2008-11-12 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
| EP1670925B1 (en) | 2003-10-02 | 2013-05-01 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
| EP1780269B1 (en) | 2004-02-23 | 2009-07-08 | Crucell Holland B.V. | Virus purification methods |
| WO2005095578A1 (en) * | 2004-03-05 | 2005-10-13 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
| EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
| ES2432655T3 (es) | 2004-09-09 | 2013-12-04 | Novartis Vaccines And Diagnostics Gmbh | Reducción de riesgos iatrogénicos potenciales asociados con antígenos de vacunas |
| JP2006090864A (ja) * | 2004-09-24 | 2006-04-06 | Denka Seiken Co Ltd | ワクチン中の特定成分の含量を求める方法 |
| KR20120128162A (ko) | 2004-12-08 | 2012-11-26 | 메디뮨 엘엘씨 | 인플루엔자 백신 조성물의 제조 방법 |
| WO2006067122A2 (en) | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| AU2006233800B2 (en) | 2005-04-11 | 2011-07-07 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| DK1907536T3 (da) * | 2005-07-22 | 2010-07-19 | Crucell Holland Bv | Cellelinie til produktion af coronavira |
| DK1951296T4 (da) | 2005-11-01 | 2014-09-01 | Novartis Vaccines & Diagnostic | Celleafledte viral vacciner med lave niveauer af restcelle-DNA |
| PT2634242T (pt) | 2006-07-14 | 2017-07-12 | Patheon Holdings I B V | Processo melhorado para cultura de células |
| EP2176398B1 (en) * | 2007-07-03 | 2016-12-28 | Transgene SA | Immortalized avian cell lines |
| CN101939330B (zh) * | 2007-12-13 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | 新型风疹e1包膜蛋白变体及其在检测抗风疹抗体中的用途 |
| EP2889042A3 (en) * | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
| WO2009152181A1 (en) * | 2008-06-11 | 2009-12-17 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
| PL2307538T3 (pl) * | 2008-07-15 | 2016-03-31 | Crucell Holland Bv | Skalowalny proces do hodowania komórek PER.C6 i wytwarzania z nich produktów |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| WO2010046335A1 (en) * | 2008-10-21 | 2010-04-29 | Crucell Holland B.V. | Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions |
| US20110217330A1 (en) | 2008-11-05 | 2011-09-08 | Bruno Rene Andre | Novel method |
| PL2454364T3 (pl) | 2009-07-16 | 2014-09-30 | Crucell Holland Bv | Produkcja wirusa polio o wysokim mianie do produkcji szczepionki |
| WO2011139717A1 (en) | 2010-04-26 | 2011-11-10 | Novartis Ag | Improved production of virus replicon particles in packaging cells |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012103361A1 (en) | 2011-01-26 | 2012-08-02 | Novartis Ag | Rsv immunization regimen |
| US20140271829A1 (en) | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
| EP2766385A2 (en) | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| CN102526720B (zh) * | 2012-01-11 | 2013-12-11 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种流感病毒疫苗的制备方法 |
| WO2013131898A1 (en) | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Improved vaccination against influenza |
| CN102631673A (zh) * | 2012-04-17 | 2012-08-15 | 金宇保灵生物药品有限公司 | 口蹄疫疫苗浓缩纯化方法 |
| EP2970843B1 (en) | 2013-03-15 | 2021-09-01 | Genzyme Corporation | High-density cell banking methods |
| JP6760927B2 (ja) | 2014-09-18 | 2020-09-23 | ジェンザイム・コーポレーション | 超高密度細胞バンキング方法 |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| BR112017012895A2 (pt) | 2014-12-17 | 2018-02-06 | Fundacion Para La Investig Medica Aplicada | construto de ácido nucleico e seu uso, vetor, célula hospedeira, partícula viral, composição farmacêutica, kit, método de tratamento de uma afecção, processo de produção de partículas virais |
| PT3233129T (pt) | 2014-12-17 | 2020-04-15 | Fundacion Para La Investig Medica Aplicada | Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições |
| CA2990745A1 (en) * | 2015-07-07 | 2017-01-12 | Seqirus UK Limited | Influenza potency assays |
| ES2642723B1 (es) | 2016-05-12 | 2018-10-22 | Servizo Galego De Saúde (Sergas) | Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias. |
| WO2019090233A2 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
| KR20200015323A (ko) | 2018-08-03 | 2020-02-12 | 에릭스바이오(주) | 바이러스 치료 장치 또는 백신 제조 장치 |
| BR112021006881A2 (pt) | 2018-10-12 | 2021-07-13 | Vivet Therapeutics | transgene otimizado por códon para o tratamento de colestase intra-hepática familiar progressiva tipo 3 (pfic3) |
| WO2020102723A1 (en) | 2018-11-16 | 2020-05-22 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| KR20220007077A (ko) | 2019-05-08 | 2022-01-18 | 다케다 백신즈 인코포레이티드 | 불활성화 바이러스 조성물 및 지카 백신 제형 |
| AR123168A1 (es) | 2020-08-06 | 2022-11-02 | Fundacion Para La Investig Medica Aplicada | Partículas virales para uso en el tratamiento de tauopatías tales como enfermedades de alzheimer mediante terapia génica |
| US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
| EP4225782A1 (en) | 2020-10-09 | 2023-08-16 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| AR127455A1 (es) | 2021-10-28 | 2024-01-24 | UCB Biopharma SRL | Constructos de ácido nucleico, vectores víricos y partículas víricas |
| WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| WO2024059507A1 (en) | 2022-09-12 | 2024-03-21 | Akero Therapeutics, Inc. | Fgf21 mutant polypeptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547779A (en) * | 1968-12-18 | 1970-12-15 | Merck & Co Inc | Process for producing purified concentrated influenza virus |
| US5192539A (en) * | 1988-07-21 | 1993-03-09 | Akzo N.V. | Infectious bursal disease virus production in continuous cell lines |
| FR2723740B1 (fr) * | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| US5989805A (en) * | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
-
1999
- 1999-11-26 EP EP99203983A patent/EP1103610A1/en not_active Withdrawn
-
2000
- 2000-11-24 PT PT00204190T patent/PT1108787E/pt unknown
- 2000-11-24 JP JP2001540125A patent/JP4331432B2/ja not_active Expired - Lifetime
- 2000-11-24 DE DE60017234T patent/DE60017234T3/de not_active Expired - Lifetime
- 2000-11-24 MX MXPA02005237A patent/MXPA02005237A/es active IP Right Grant
- 2000-11-24 KR KR1020067020200A patent/KR20060107868A/ko active IP Right Grant
- 2000-11-24 CA CA2392653A patent/CA2392653C/en not_active Expired - Lifetime
- 2000-11-24 EP EP00204190A patent/EP1108787B2/en not_active Expired - Lifetime
- 2000-11-24 AU AU25572/01A patent/AU775966B2/en not_active Expired
- 2000-11-24 EP EP04105656A patent/EP1514937A1/en not_active Withdrawn
- 2000-11-24 CN CNB008186634A patent/CN1306033C/zh not_active Expired - Lifetime
- 2000-11-24 KR KR1020027006678A patent/KR100683374B1/ko active IP Right Grant
- 2000-11-24 NZ NZ527942A patent/NZ527942A/en unknown
- 2000-11-24 ES ES00204190T patent/ES2235770T5/es not_active Expired - Lifetime
- 2000-11-24 BR BR0015846-1A patent/BR0015846A/pt not_active IP Right Cessation
- 2000-11-24 IL IL14978800A patent/IL149788A0/xx unknown
- 2000-11-24 SI SI200030638T patent/SI1108787T2/sl unknown
- 2000-11-24 EA EA200200604A patent/EA006136B1/ru not_active IP Right Cessation
- 2000-11-24 AT AT00204190T patent/ATE286537T1/de active
- 2000-11-24 DK DK00204190T patent/DK1108787T4/da active
- 2000-11-24 WO PCT/NL2000/000862 patent/WO2001038362A2/en active IP Right Grant
-
2002
- 2002-05-21 IL IL149788A patent/IL149788A/en unknown
- 2002-05-22 ZA ZA200204078A patent/ZA200204078B/xx unknown
- 2002-05-27 NO NO20022500A patent/NO333527B1/no not_active IP Right Cessation
-
2004
- 2004-01-09 HK HK04100143A patent/HK1057236A1/xx not_active IP Right Cessation
- 2004-08-05 AU AU2004203642A patent/AU2004203642A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2235770T5 (es) | Produccion de vacunas. | |
| US7964198B2 (en) | Production of vaccines | |
| US7550284B2 (en) | Production of vaccines | |
| US7527961B2 (en) | Production of vaccines | |
| Kistner et al. | Development of a mammalian cell (Vero) derived candidate influenza virus vaccine | |
| Girard et al. | The 2009 A (H1N1) influenza virus pandemic: A review | |
| ES2297028T3 (es) | Produccion de virus, aislados virales y vacunas. | |
| Baz et al. | Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge | |
| Do Hwang et al. | Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination | |
| Wang et al. | A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice | |
| Coulson | Expanding diversity of glycan receptor usage by rotaviruses | |
| Shin et al. | Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines | |
| Yang et al. | Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets | |
| WO2012060678A2 (es) | Vacunas novedosas contra el virus de la influencia pandémica a/h1n1 | |
| JP5918870B2 (ja) | インフルエンザに対する改善されたワクチン接種 | |
| Wang et al. | Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice | |
| Wang | Universal Swine Influenza Antigen and Vaccine | |
| Larionova et al. | Journal of Vaccines & Vaccination | |
| Pras | Universal Influenza Vaccines |